Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland

Gynecologic Oncology

Volumn 126, Issue 2, 2012, Pages 241-244

  Koskela Niska, Virpi ^a   Riska, Annika ^a   Lyytinen, Heli ^a   Pukkala, Eero ^b   Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

Author keywords

Continuous; Estrogen; Progestin; Sequential

Indexed keywords

DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; GESTAGEN; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; PROGESTERONE; TRIMEGESTONE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FINLAND; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIMARY FALLOPIAN TUBE CARCINOMA; PRIORITY JOURNAL; REIMBURSEMENT; RISK FACTOR; SALPINGECTOMY; STANDARDIZED INCIDENCE RATIO; TREATMENT DURATION; UTERINE TUBE CARCINOMA;

COHORT STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FALLOPIAN TUBE NEOPLASMS; FEMALE; FINLAND; HUMANS; HYSTERECTOMY; MIDDLE AGED; PROGESTINS;

EID: 84862850538     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.045     Document Type: Article

References (36)

1. Pfeiffer P, Moquensen H, Amtrup F, Honore E. Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish Cancer Registry in a five-year period. Acta Oncol 1989;28:7-11. (Pubitemid 19113613)
2. Rosenblatt KA,WeissNS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol 1989;35:236-9. (Pubitemid 19268565)
3. Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97. Int J Cancer 2003;104:643-5. (Pubitemid 36337266)
4. Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in United States. Gynecol Oncol 2007;107:392-7. (Pubitemid 350160878)
5. RiskaA, Sund R, Pukkala E, Gissler M, Leminen A. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. Int J Cancer 2006;120:1351-4.
6. Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM, et al. Australian cancer study group. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2008;12:1598-603. (Pubitemid 351294969)
7. Rosen AC, Reiner A, Klein M, Lahousen M, Graf AH, Vavra N, et al. Prognostic factors in primary fallopian tube carcinoma. Austrian cooperative study group for fallopian tube carcinoma. Gynecol Oncol 1994;53:307-13.
8. Papadimitriou CA, Markaki S, Lianos E, Peitsidis P, Vourli G, Nikitas N, et al. Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. Eur J Gynaecol Oncol 2009;30:389-95.
9. Raba G, Laudanski P, Kanczuga-Koda L. Immunohistochemical findings in primary fallopian tube cancer. Case report. Eur J Gynaecol Oncol 2010;31:120-2.
10. Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist 2006;11:902-12. (Pubitemid 44373763)
11. Riska A, Finne P, Alftan H, Anttila T, Jalkanen J, Sorvari T, et al. Past chlamydial infection is not associated with primary fallopian tube carcinoma. Eur J Cancer 2006;42:1835-8. (Pubitemid 44149083)
12. Riska A, Finne P, Koskela P, Alftan H, Jalkanen J, Lehtinen M, et al. Human papilloma virus infection and primary fallopian tube carcinoma: a seroepidemiological study. BJOG 2007;114:425-9. (Pubitemid 46393294)
13. Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, et al. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol 2010;118:155-9.
14. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-60. (Pubitemid 44901007)
15. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009;113:65-73.
16. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9. (Pubitemid 24207996)
17. Keskimäki I, Aro S, Teperi J. Regional variation in surgical procedure rates in Finland. Scand J Soc Med 1994;22:132-8. (Pubitemid 24191574)
18. Rothman KJ, Greenland S.Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven Publishers; 1998. p. 264.
19. Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, et al. BRCA1 and BRCA2 mutation among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001;9:424-30. (Pubitemid 32586065)
20. Syrjäkoski L, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:1529-31.
21. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacks C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-75.
22. Adachi K, Kurachi H, Homma H, Adachi H, Imai T, Sakata M, et al. Estrogen induces epidermal growth factor (EGF) receptor and its ligands in human fallopian tube: involvement of EGF but not transforming growth factor-alpha in estrogen-induced tubal cell growth in vitro. Endocrinology 1995;136:2110-9.
23. International Agency for Research on Cancer. Combined estrogen-progestogen contraception and combined estrogen-progestogen postmenopausal therapy. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 91. Lyon: IARC Press; 2003.
24. Lacey JV, Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health - AARP diet and healthy study cohort. Cancer 2007;109:1303-11. (Pubitemid 46466557)
25. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009;114:1197-204.
26. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperger C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results of the women's health initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
27. Anderson GL, Chlebovski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13:476-86.
28. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008;123:933-41. (Pubitemid 352032424)
29. Bakken K, Founier A, Lund E, Waasth M, Dumeaux V, Clavel-Chapleon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. Int J Cancer 2011;128:144-56.
30. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9. (Pubitemid 46095865)
31. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35. (Pubitemid 46092026)
32. Koskela-Niska V, Lyytinen H, Riska A, Pukkala E, Ylikorkala O. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study. Climacteric 2012, http://dx.doi.org/10.3109/13697137.2012. 663818.
33. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009;19:58-64.
34. Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas 1999;32:141-5. (Pubitemid 29389728)
35. Rimpelä AH, Pukkala EI. Cancers of affluence: positive social class gradient and rising incidence trend in some cancer forms. Soc Sci Med 1987;24:601-6. (Pubitemid 17090650)
36. Tavassoli FA, Devilee P, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.